GLP-1 Research Cycle Summary — May 26, 2026
This research cycle tracked the most significant developments in the GLP-1 and obesity space from May 21–26, 2026. The dominant themes were: (1) a potential paradigm shift into oncology, (2) Novo Nordisk's dual EU regulatory wins, and (3) the continued acceleration of next-generation pipeline and competitive dynamics.
1. Cancer Risk Reduction — A New TAM Frontier
The single most consequential new finding this cycle: a Cleveland Clinic study of 10,000+ patients found GLP-1 users had 50% lower lung cancer progression risk and 43% lower breast cancer progression risk versus matched controls on DPP-4 inhibitors. The effect appears drug-driven, not just metabolic — tumors with more GLP-1 receptors were less likely to metastasize. This opens a potential oncology TAM that consensus estimates do not yet reflect.
2. Novo Nordisk: Dual EU CHMP Wins (Wegovy Pill + 7.2 mg Injection)
On May 22, the EMA's CHMP recommended approval of both the Wegovy pill (16.6% weight loss; first oral GLP-1 in EU) and the Wegovy 7.2 mg single-dose pen (20.7% weight loss; 31% of patients ≥25%). EU launches expected H2 2026. These wins materially expand Novo's addressable market at a time when the stock desperately needs positive catalysts (down ~32% over the past year).
3. Retatrutide TRIUMPH-1: Detailed Data Deliver Bariatric-Level Results
Full topline data from Lilly's Phase 3 TRIUMPH-1 trial confirmed 28.3% mean weight loss at 80 weeks (12 mg dose), with 65.3% of patients reaching BMI <30. A blinded extension to 104 weeks showed 30.3% weight loss. Dysesthesia emerged as a new safety signal (5.1–12.5% vs 0.9% placebo). Detailed results to be presented at ADA Scientific Sessions in June.
4. Compounding Crackdown Intensifies
The FDA's enforcement campaign continues to escalate — 30 warning letters to telehealth firms in March 2026 alone, and the agency has proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Hims & Hers pivoted from adversary to Novo partner after a two-day legal clash. The compounding window is closing, which is pricing-power-positive for branded products.
5. Emerging Science: cAMP Mechanism, AI-Discovered Side Effects, and Anti-Inflammatory Effects
- NIH study (Nature Metabolism): identified cAMP signaling in area postrema neurons as the intracellular driver of GLP-1 weight loss; co-administering PDE4 inhibitor roflumilast extended the effect, suggesting combination therapy opportunities.
- Penn/Reddit AI study (Nature Health): LLMs analyzing 400K Reddit posts identified menstrual irregularities, chills/hot flashes, and fatigue as underreported side effects — hypothalamus-mediated mechanisms are plausible but causation is unproven.
- Cell Metabolism study: semaglutide reduced osteoarthritis inflammation and cartilage destruction independent of weight loss.
6. Viking Therapeutics: M&A Speculation Intensifies
VKTX (~$3.6B market cap) is the most-discussed obesity acquisition target. Phase 2 oral VK2735 showed 12.2% weight loss at 13 weeks (no plateau). Phase 3 VANQUISH trials fully enrolled. $603M cash into 2028. Polymarket bettors and analysts ($95 PT vs $30 price) see a takeout as increasingly likely.
7. Other Developments
- Novo Nordisk partnered with OpenAI to embed AI across drug discovery and manufacturing
- Hims & Hers launched first generic semaglutide in a G7 country (Canada, C$149/month)
- Novo Nordisk's POSEIDON study: 2 in 5 CVD patients have cardiovascular inflammation, building the case for anti-inflammatory GLP-1 applications
- 16 new GLP-1 drugs projected to enter US market 2026–2029
Open Threads
- CagriSema FDA decision (December 2026) — no update this cycle
- FDA final rule on 503B compounding exclusion — proposed but not yet finalized
- Retatrutide TRIUMPH-2 (T2D) and TRIUMPH-3 (CVD) results — still pending; ADA June 2026 may bring updates
- Medicare GLP-1 Bridge program launch — July 1, 2026, still 5 weeks out